Mechanism of Action of Apremilast
Apremilast works by selectively inhibiting phosphodiesterase 4 (PDE4), which increases intracellular cyclic adenosine monophosphate (cAMP) levels, leading to downstream modulation of both pro-inflammatory and anti-inflammatory mediators. 1
Primary Mechanism
PDE4 Inhibition: Apremilast is a small-molecule oral inhibitor specific for PDE4, the major enzyme responsible for hydrolyzing cAMP in immune and non-immune cells 2
cAMP Elevation: By blocking PDE4, apremilast prevents the breakdown of cAMP, resulting in increased intracellular cAMP concentrations 1
Broad Immunomodulation: The elevated cAMP levels trigger a cascade of effects rather than targeting a single inflammatory mediator, distinguishing it from biologics that target specific cytokines like TNF-α or IL-17 3
Downstream Signaling Pathways
The increased cAMP works through multiple intracellular effectors:
Protein Kinase A (PKA): Activates PKA, leading to phosphorylation of CREB (cAMP response element-binding protein) and ATF-1 (activating transcription factor-1) 4
Exchange Proteins Activated by cAMP (Epac): Both Epac1 and Epac2 pathways are involved in mediating apremilast's immunoregulatory effects 5
NF-κB Inhibition: Reduces NF-κB transcriptional activity, a key regulator of inflammatory gene expression 4
Effects on Inflammatory Mediators
Pro-inflammatory mediator reduction 2:
- Decreases TNF-α production
- Reduces IL-23, IL-6, IL-1α expression
- Lowers inducible nitric oxide synthase (iNOS) levels
- Decreases interferon-α production by plasmacytoid dendritic cells 4
Anti-inflammatory mediator enhancement 2:
- Increases IL-10 (anti-inflammatory cytokine) production
- Modulates other anti-inflammatory signals to restore homeostatic balance 3
Cellular Targets
Innate Immunity: Primary effects on monocytes, macrophages, and dendritic cells, with selective effects on innate immune responses 4
T Cells: Inhibits T-cell cytokine production and modulates Th1, Th17, and type 1 interferon pathways 2
Limited B Cell Effects: Minimal impact on B-cell immunoglobulin secretion, distinguishing it from immunosuppressive agents 4
Important Clinical Distinctions
The specific mechanism(s) by which apremilast exerts its therapeutic action is not fully defined, as acknowledged by the FDA 1. This reflects that while the PDE4 inhibition and cAMP elevation are well-established, the complete downstream cascade leading to clinical benefit remains incompletely characterized.
Anti-inflammatory, not immunosuppressive: Unlike biologics or traditional immunosuppressants, apremilast restores balance between pro- and anti-inflammatory signals rather than broadly suppressing immune function 6
No cereblon binding: Despite sharing a phthalimide ring structure with thalidomide, apremilast lacks the glutarimide ring and does not bind to cereblon, avoiding thalidomide-related mechanisms and teratogenic effects 4